Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of Pro-longevity drugs on Lipid profile, link between lipid signalling and longevity

ABSTRACT: We report the effect of four lifespan modifying drugs and of combinations of these drugs on lipid profile in Caenorhabditis elegans. We investigated drug-drug interactions and identified beneficial drug interactions between drugs selected to target synergistic longevity mechanisms and pathways. We employ ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS) to compare the abundance of lipid species in treated and control animals. Adult nematodes were treated with rapamycin, rifampicin, psora-4 and allantoin and combinations of these compounds and the resulting change in lipid profiles, specifically in those of triacylglycerol (TAG), phosphatidylcholine (PC) and phosphatidylethanolamine (PE) were determined. We quantified changes resulting from treatment with the drug combinations relative to untreated controls and relative to animals treated with each constituent single drugs. We further determined the dependence of changes in lipid profiles on genes know to affect lipid metabolism using strains carrying mutations in these pathways. In particular, we determined lipid profiles in genetic model of caloric restriction (eat-2), strain lacking homolog of TGFβ (daf-7) and in strain lacking the SREBP/sbp-1 transcription factor.

INSTRUMENT(S): Liquid Chromatography Tandem MS (LC-MS/MS)

PROVIDER: MTBLS648 | MetaboLights | 2018-06-08

REPOSITORIES: MetaboLights

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	PC_Allan1.d.zip	Other
	PC_Allan2.d.zip	Other
	PC_Allan3.d.zip	Other
	PC_N2-1.d.zip	Other
	PC_N2-2.d.zip	Other

Items per page:

1 - 5 of 293

Similar Datasets

Transcriptomic profiles of tissues from rats treated with drug combinations

Project description:Transcriptomic profiles of tissues from rats treated with drug combinations

| PRJNA488241 | ENA

Gene expression changes were assessed in tumor cells treated with epigenetic inhibitors and after drug withdrawal

Project description:Sequential therapy is a promising strategy to enhance antitumor efficacy; however, the rational design of sequential drug treatments remains challenging. Here, we introduce an AI framework, AlphaTherapy, which can design sequential drug combinations for cancer treatment. Analysis of AlphaTherapy-predicted combinations and large-scale in vitro validation revealed that the first drug in effective anti-tumor combinations often targets transcription, particularly epigenetic inhibitors. To investigate how epigenetic drugs enhance the efficacy of subsequent treatments, RNA-seq was performed on tumor cells treated with epigenetic inhibitors followed by drug withdrawal to assess gene expression changes.

2025-12-22 | GSE306072 | GEO

The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies

Project description:Our ability to predict the effects of drug combinations is limited, in part by limited understanding of how the transcriptional response of two monotherapies results in that of their combination. We performed the first analysis of matched time course RNAseq profiling of cells treated with both single drugs and their combinations. The transcriptional signature of the synergistic combination we studied had unique gene expression not seen in either constituent monotherapy. This can be explained mechanistically by the sequential activation of transcription factors in time in the gene regulatory network. The nature of this transcriptional cascade suggests that drug synergy may ensue when the transcriptional responses elicited by two unrelated individual drugs are correlated. We used these results as the basis of a simple prediction algorithm attaining an AUROC of 0.77 in the prediction of synergistic drug combinations in an independent dataset.

2020-04-28 | GSE149428 | GEO

Transcriptomic profiles of tissues from rats treated with drug combinations [Study 2]

Project description:Transcriptomic profiles of tissues from rats treated with drug combinations [Study 2]

| PRJNA488236 | ENA

Transcriptomic profiles of tissues from rats treated with drug combinations [Study 1]

Project description:Transcriptomic profiles of tissues from rats treated with drug combinations [Study 1]

| PRJNA488229 | ENA

Transcriptomic profiles of tissues from rats treated with drug combinations [Study 3]

Project description:Transcriptomic profiles of tissues from rats treated with drug combinations [Study 3]

| PRJNA488244 | ENA

Activated SKN-1 alters the longevity trajectory of long-lived C. elegans mutants

Project description:In the presence of stressful environments, the SKN-1 cytoprotective transcription factor is activated to induce the expression of gene targets that can restore homeostasis. However, constitutive activation of SKN-1 results in diminished health and a reduction of lifespan. Here we demonstrate the necessity to regulate the activity of SKN-1 for maintaining the longevity promoting responses associated with impaired daf-2/insulin receptor signaling, the eat-2 model of caloric restriction, and glp-1-dependent loss of germ cell proliferation. A hallmark of animals with constitutive SKN-1 activation is the age-dependent loss of somatic lipids and this phenotype is linked to the general reduction in survival in animals harboring the skn-1gf allele, but surprisingly, daf-2lf; skn-1gf double mutant animals do not redistribute somatic lipids which suggests the insulin signaling pathway functions downstream of SKN-1 in the maintenance of lipid distribution. As expected, eat-2lf; skn-1gf double mutant animals, which independently activate SKN-1, continue to display somatic lipid depletion in older ages with and without the skn-1gf activating mutation but animals lacking a proliferating germline do not redistribute somatic lipids, which supports a genetic model where SKN-1 activity is an important regulator of lipid mobilization in response to food availability to fuel the developing germline by engaging the daf-2/insulin receptor pathway.

2024-07-01 | GSE270810 | GEO

Expression data from Adra1a, Adra1b and Adra1d KO mice treated with milnacipran.

Project description:Investigation of the role of Adra1 subtypes and their impact on antidepressant drugs efficiency. Adra1a, Adra1b and Adra1d KO mice were chronically treated by antidepressant drug milnacipran. Microarray experiment was applied to compare up and downregulated genes after chronic treatment of milnacipran itself on w/t animals and the effec of this drug when treated the mice with ablation of Adra1a, Adra1b or Adra1d genes, respectively.

2025-07-31 | GSE272818 | GEO

Optimized high-order drug mixtures improve colorectal carcinoma treatment via inactivationof MAP kinase signaling pathway and cell cycle alteration

Project description:Colorectal carcinoma is currently treated with a combination of chemotherapeutic drugs supplemented with targeted drugs. Since there is an eminent need to improved therapeutic success we employed the phenotypically-driven therapeutically guided multidrug optimization (TGMO) technology to identify personalized optimal drug combinations (ODCs). Using this technology we obtained low dose synergistic and selective ODCs for a panel of human colorectal carcinoma cells that remained active in 3-dimensional heterotypic co-culture models. From RNA sequencing and phosphoproteomics analysis we noticed considerable overlap in the top 20 most active kinases in all cell lines and that the mechanism converges around MAP kinase signaling and cell cycle inhibition despite differential cell mutation status, transcript expression levels and protein kinase activity. RNA sequencing revealed differentially expressed genes that confirmed these observations. These combinations were subsequently translated to in vivo models. Interestingly, the optimized drug mixtures reduced tumor volume with 80% and significantly outperformed the standard chemotherapy (FOLFOX) in these models, while preventing toxicity, observed after FOLFOX treatment. Pharmacokinetics studies demonstrated that the combinations supported significantly enhanced drug bioavailability.

2021-09-09 | PXD016604 | Pride

Comparative genomic hybridization by array of east haploid and heterozygous essential deletion pools treated with compounds synergistic with fluconazole to identify sensitive and resistant mutants

Project description:The haploid and the heterozygous essential S.cerevisiae deletion pools were grown in the presence of compounds that we found to be synergistic with fluconazole. We also treated the deletion pools with combinations of those drugs and fluconazole to interrogate the mechanism of action of the drug interactions. These experimental samples were hybridized against DMSO or water control samples. The resulting hybridization pattern informs about sensitive and resistant yeast deletion mutants.

2011-09-07 | E-MTAB-394 | biostudies-arrayexpress